scholarly journals A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings

2022 ◽  
Author(s):  
L. Alison McInnes ◽  
Jimmy J. Qian ◽  
Rishab S. Gargeya ◽  
Charles DeBattista ◽  
Boris D. Heifets
Keyword(s):  
Retrospective Analysis ◽  
Real World ◽  
Intravenous Therapy

scholarly journals Real-World Fetal Exposure to Acne Treatments in the United States: A Retrospective Analysis from 2006 to 2015

Drug Safety ◽  
2021 ◽  
Vol 44 (4) ◽  
pp. 447-454 ◽  
Author(s):  
Yasser Albogami ◽  
Amir Sarayani ◽  
Juan M. Hincapie-Castillo ◽  
Almut G. Winterstein
Keyword(s):  
United States ◽  
Retrospective Analysis ◽  
Real World ◽  
The United States ◽  
Fetal Exposure

scholarly journals Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Laurenz T. Fischer ◽  
Daniel A. Hochfellner ◽  
Lisa Knoll ◽  
Tina Pöttler ◽  
Julia K. Mader ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Real World ◽  
Cardiovascular Events ◽  
Care Center ◽  
Tertiary Care ◽  
Lipid Lowering ◽  
Tertiary Care Center ◽  
Pcsk9 Inhibitors ◽  
Real World Data ◽  
Pcsk9 Inhibitor

Abstract Background The lipid-lowering and positive cardiovascular effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors was shown in several studies, hence, they are more widely used in the lipid-lowering management of individuals with high cardiovascular risk. As real-world data are still scarce, specifically in patients with type 2 diabetes (T2D), the aim of this retrospective analysis was to investigate the efficacy of PCSK9 inhibitors in lowering low-density lipoprotein cholesterol (LDL-C) in an outpatient clinic of a tertiary care center in routine care. Methods A retrospective analysis of data extracted from the electronic patient record was performed. Patients who were routinely prescribed with PCSK9 inhibitor therapy (alirocumab or evolocumab) during the years 2016 and 2019 were included in the analysis. Characteristics of the patient population, the effects on LDL-C and HbA1c levels as well as subsequent cardiovascular events were assessed over an observation period of 18 months. Results We identified 237 patients treated with PCSK9 inhibitors between January 2016 and September 2019. Almost all patients (97.5%) received PCSK9 inhibitors for secondary prevention. 26.2% of the population had a concomitant diabetes diagnosis. Intolerance to statins (83.1%), ezetimibe (44.7%) or both agents (42.6%) was reported frequently. Three months after initiation of PCSK9 inhibitor therapy, 61.2% of the patients achieved LDL-C levels < 70 mg/dl, and 44.1% LDL-C levels < 55 mg/dl. The median LDL-C was lowered from 141 mg/dl at baseline, to 60 mg/dl after 3 months and 66 mg/dl after 12 months indicating a reduction of LDL-C as follows: 57.5% after 3 months and 53.6% after 12 months. After 3 months of observation, target achievement of LDL-C was higher in patients with T2D compared to non-diabetes patients; < 55 mg/dl: 51% vs. 41.5%; < 70 mg/dl 69.4 vs. 58.5%. After 12 months even more pronounced target LDL achievement in T2D was demonstrated < 55 mg/dl: 58.8% vs. 30.1%; < 70 mg/dl 70.6 vs. 49.6%. Patients with insufficiently controlled T2D (HbA1c > 54 mmol/mol) had a higher reduction in LDL-C but still were more likely to subsequent cardiovascular events. Conclusions Significant reductions in LDL-C and a high percentage of patients achieving recommended treatment targets were observed. The percentage of patients with T2D meeting recommended LDL-C targets was higher than in those without T2D. Still some patients did not achieve LDL-C levels as recommended in current guidelines. Special attention to the characteristics of these patients is required in the future to enable achievement of treatment goals and avoid adverse cardiovascular outcomes.

scholarly journals Retrospective analysis of the real-world utilization of ranibizumab in wAMD

2012 ◽  
Vol 90 ◽  
pp. 0-0
Author(s):  
R TADAYONI ◽  
F HOLZ ◽  
TGH HEAH ◽  
S HELDNER ◽  
FOR THE AURA STEERING COMMITTEE
Keyword(s):  
Retrospective Analysis ◽  
Real World ◽  
The Real

scholarly journals Impact of Switching to Fingolimod Versus Injectable Disease-Modifying Therapy Cycling on Risk of Multiple Sclerosis–Related Relapses: A Retrospective Analysis

2020 ◽  
pp. 0000-0000
Author(s):  
Maria Cecilia Vieira ◽  
Yunfeng Li ◽  
Xiangyi Meng ◽  
Huanxue Zhou ◽  
Olivia Wenxian Piao ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Relapse Rate ◽  
Real World ◽  
Negative Binomial ◽  
Office Visit ◽  
Negative Binomial Regression ◽  
Negative Binomial Regression Model ◽  
Corticosteroid Administration ◽  
Disease Modifying Therapy ◽  
Disease Modifying

Abstract Background: Clinical and real-world studies have shown significant reductions in MS relapses in patients receiving fingolimod versus injectable disease-modifying therapies (iDMTs). The objective was to compare MS relapse rate and incidence in patients switching from an iDMT to fingolimod with those cycling from one iDMT to another or those remaining on their original iDMT. Methods: A retrospective analysis was performed using MarketScan® Commercial and Medicare Supplemental claims data (July-1-2010–June-30-2016). Adult MS patients receiving ≥1 iDMT during the study were included. Relapses were identified from an MS-related hospitalization, outpatient ER or office visit, and corticosteroid administration. Annualized relapse rate ratio was estimated by negative binomial regression model with repeat-measures. Results: Of 16,352 patients, 1,110 were switchers to fingolimod, 908 were iDMT cyclers, and 14,334 were non-switchers. At baseline, rate and incidence of MS relapses were higher in switchers and iDMT cyclers versus non-switchers (P &lt; .001); mean (SD) relapse rates declined from 0.4 (0.7), 0.4 (0.7), and 0.2 (0.5) at baseline to 0.2 (0.5), 0.3 (0.6), and 0.1 (0.4) after follow-up in switchers, iDMT cyclers, and non-switchers, respectively. Relapse incidence also declined in each cohort. The highest reductions in relapse rate and incidence were observed in switchers to fingolimod, where relapse risk was significantly reduced versus iDMT cyclers (22%; P = .0433) and non-switchers (47%; P &lt; .001). Conclusions: This real-world study provides evidence that patients switching from an iDMT to fingolimod have the highest reductions in annualized rate and incidence of MS relapses, and significantly reduced risk of relapse, versus iDMT cyclers and non-switchers.

scholarly journals Effectiveness and safety of secukinumab in axial spondyloarthritis and psoriatic arthritis: A retrospective analysis of its real-world usage from India

2020 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
Kavitha Mohanasundaram ◽  
Sham Santhanam ◽  
Hema Murugesan ◽  
Thilagavthy Nambi ◽  
Raja Natarajan
Keyword(s):  
Psoriatic Arthritis ◽  
Retrospective Analysis ◽  
Real World ◽  
Axial Spondyloarthritis

A Retrospective Analysis of Clinical Use and Outcomes Using Viable Placental Membrane Allografts in Chronic Wounds

2021 ◽  
Vol 33 (12) ◽  
pp. 329-333
Author(s):  
Laura Swoboda
Keyword(s):  
Retrospective Analysis ◽  
Real World ◽  
Chronic Wounds ◽  
Chronic Wound ◽  
Arterial Disease ◽  
Wound Management ◽  
Foot Ulcers ◽  
Controlled Trials ◽  
Clinical Use ◽  
Exposed Bone

Introduction. Viable placental membrane (vPM) has been shown to decrease time to healing, adverse wound events, and wound-related infections. Wound research exclusion criteria commonly exclude wound types other than diabetic foot ulcers and venous leg ulcers (VLUs), comorbidities including peripheral arterial disease (PAD) and uncontrolled diabetes mellitus (DM), and wounds with exposed bone or tendon. Objective. This retrospective research study evaluated the clinical use and outcomes of the vPM with living mesenchymal stem cells used in chronic wound management in the community hospital outpatient department setting with the goal of comparing real-world use and outcomes of the product with use and outcomes described in the chronic wound literature. Materials and Methods. A retrospective analysis on vPM treatments at a Wisconsin academic health system’s community hospitals. Participants included all patients who received vPM therapy between July 1, 2016, and August 21, 2019. Results. A total of 89 patients received vPM treatment during the study period (mean age, 70 years; 69% male [n = 61], 31% female [n = 28]). Wound types were 54% diabetic or neuropathic foot ulcers (n = 48), 17% VLUs (n = 15), 7% pressure injuries (n = 6), and 22% atypical wounds (n = 20). The average wound duration prior to vPM initiation was 104 days. Average wound size at presentation was 6.9 cm2. Of study participants 54% had PAD (n = 48), 63% had DM (n = 56), 33.7% had DM and PAD (n = 30), and 17% had exposed bone or tendon (n = 15). Average adjusted time to healing after initiation of vPM was 81.2 days. The percentage of wounds healed 12 weeks after initiation of vPM treatment was 57%. Conclusions. Effectiveness of vPM observed in controlled trials also was observed in this real-world study on vPM for multiple wound types, patients with comorbidities including PAD and uncontrolled DM, and wounds with exposed bone or tendon. Results of this study were not statistically different from those reported in the literature. More randomized controlled trials are needed to explore the efficacy of vPM on patient presentations common to wound healing centers.

NCOG-14. REAL-WORLD RETROSPECTIVE ANALYSIS OF TUMOR TREATING FIELDS IN THE TREATMENT OF HIGH-GRADE GLIOMA BASED ON CHINESE POPULATION

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi154-vi155
Author(s):  
Lingchao Chen ◽  
Junrui Chen ◽  
Kun Song ◽  
Jingtao Nie ◽  
Dongxiao Zhuang ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Real World ◽  
Chinese Population ◽  
Adverse Reactions ◽  
High Grade Glioma ◽  
High Grade ◽  
Newly Diagnosed ◽  
Efficacy Data ◽  
Tumor Treating Fields ◽  
Recurrent Gbm

Abstract OBJECTIVES Tumor Treating Fields (TTFields) has been approved for the treatment of newly diagnosed and relapsed glioblastoma（GBM）in China in 2020. Only few TTFields data in Asia patients were reported. This retrospective analysis is aimed at investigating the efficacy, safety and the potential relationship with biomarkers of TTFields treatment in the real-world clinical practice of the Chinese glioma population. METHODS High-grade glioma patients who were under TTFields treatment from May 2019 to May 2021 in Shanghai Huashan Hospital were analyzed, including baseline data, efficacy data and incidence of adverse events. RESULTS Eighty-two patients (median age 51.0 [26.0 - 47.0] years) with high-grade glioma were enrolled, including 60 newly diagnosed GBM, 16 recurrent GBM, and 6 WHO grade III gliomas. The median time was 9.9 (4.6-15.7) months for follow-ups, median time for TTFields treatment was 4.3(1.1-20.35) months. The median compliance rate was 90% (40%-97%). For newly diagnosed GBM (n=60) and recurrent GBM (n=16), the 6-month PFS rate were 78.4% (95%CI: 63.9-87.6) and 46.7% (95%CI: 21.2- 67.8) respectively. The 10-month OS rate were 86.3% (95%CI: 69.6- 94.2) and 60.0% (95%CI: 12.6- 88.2) respectively. The 6-month PFS rate in the IDHw/TERTm population was 69.9% (95%CI: 45.9-84.9) and 78.3% (95%CI: 46.5-92.5) in the IDHw/TERTw patients with newly diagnosed GBM. 59(72%) patients had skin-related adverse reactions, and majority are grade 1-2 (grade 1-2, 69.5%; grade 3, 2.5%). CONCLUSIONS This is the 1st retrospective analysis done using TTFields in the treatment of high-grade gliomas in the Chinese population with the largest sample size. From our short follow up, TTFields appears good efficacy among GBM patients. The incidence of skin adverse reactions is higher comparable to published data, but mainly consisted of grade1-2. Long-term efficacy data need to be further followed-up.

Sign in / Sign up

Export Citation Format

Share Document